US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OnKure Therapeutics, Inc.

2.65

-0.1100-3.99%

Volume:220.74K

Turnover:585.29K

Market Cap:35.60M

PE:-0.17

High:2.81

Open:2.67

Low:2.54

Close:2.76

Loading ...

Overview Company News Filings

We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate

Simply Wall St.

OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies

OnKure Therapeutics Is Maintained at Outperform by Oppenheimer

Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)

Onkure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

THOMSON REUTERS

Onkure Therapeutics: Expansion of Pi3ka Franchise to Include a Pan-Mutant Selective Program; Development Candidate Expected to Be Announced in Q2 2025

THOMSON REUTERS

Press Release: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

U.S. RESEARCH ROUNDUP-Apple, Coinbase Global, Nextracker

Onkure Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $32

THOMSON REUTERS

OnKure Therapeutics Initiated at Buy by Jones Trading

Oppenheimer Remains a Buy on OnKure Therapeutics (OKUR)

Onkure Therapeutics Inc - No Dose Interruptions, Delays, Reductions, or Discontinuations Reported

THOMSON REUTERS

Onkure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (Pk) Data From Its First-in-Human Pikture-01 Trial of Oki-219

THOMSON REUTERS

Onkure Therapeutics Inc - Oki-219 Well Tolerated With No Hyperglycemia and Only Grade 1 Traes

THOMSON REUTERS

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

OnKure Announces New Date for Upcoming Investor Call

OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OKUR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OKUR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OKUR\",,,,,undefined,":{"symbol":"OKUR","market":"US","secType":"STK","nameCN":"OnKure Therapeutics, Inc.","latestPrice":2.65,"timestamp":1745524800000,"preClose":2.76,"halted":0,"volume":220740,"delay":0,"floatShares":4257469,"shares":13435826,"eps":-15.280509,"marketStatus":"Pre-Mkt","change":-0.11,"latestTime":"04-25 06:46:31 EDT","open":2.67,"high":2.81,"low":2.54,"amount":585291.9094,"amplitude":0.097826,"askPrice":3.74,"askSize":100,"bidPrice":1.44,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-15.280509,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745587800000},"marketStatusCode":1,"adr":0,"listingDate":1617940800000,"exchange":"NASDAQ","adjPreClose":2.65,"postHourTrading":{"tag":"盘后","latestPrice":2.65,"preClose":2.65,"latestTime":"17:04 EDT","volume":53,"amount":140.95,"timestamp":1745528672471},"volumeRatio":2.89459813006396},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OKUR\",,,,,undefined,":{"symbol":"OKUR","floatShares":4257469,"roa":"-44.43%","roe":"-79.92%","lyrEps":-15.280509,"volumeRatio":2.89459813006396,"shares":13435826,"dividePrice":0,"high":2.81,"amplitude":0.097826,"preClose":2.76,"low":2.54,"week52Low":2.5,"pbRate":"0.34","week52High":190,"institutionHeld":0,"latestPrice":2.65,"eps":-15.280509,"divideRate":0,"volume":220740,"delay":0,"ttmEps":-15.280509,"open":2.67,"prevYearClose":8.6,"prevWeekClose":2.89,"prevMonthClose":4.3,"prevQuarterClose":4.3,"fiveDayClose":2.93,"twentyDayClose":4.74,"sixtyDayClose":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OKUR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523664639","title":"We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523664639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523664639?lang=en_us&edition=fundamental","pubTime":"2025-03-29 22:36","pubTimestamp":1743259012,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-okur/onkure-therapeutics/news/were-keeping-an-eye-on-onkure-therapeutics-nasdaqokur-cash-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NQmain","USJW.SI","PSQ","IE00B3QW5Z07.USD","NVIW.SI","OKUR","IE00B64PRP62.GBP","SQQQ","IE00BGHQF748.EUR","QLD","BK4139",".IXIC","NDAQ","MNQmain","USAW.SI","TQQQ","TSYW.SI","BK4585","BK4112","IE00BKPKM429.USD","LU2095319765.USD","QID","BK4588","LU2210149790.SGD","LU2210150020.SGD"],"gpt_icon":1},{"id":"2520621318","title":"OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520621318","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520621318?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:28","pubTimestamp":1742297280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKUR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 07:28 ET (11:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","LENZ"],"gpt_icon":0},{"id":"2518037523","title":"Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518037523","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518037523?lang=en_us&edition=fundamental","pubTime":"2025-03-12 14:00","pubTimestamp":1741759222,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics, Inc. (OKUR) has disclosed a new risk, in the Competition category. Onkure Therapeutics, Inc. faces substantial competition in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/onkure-therapeutics-faces-stiff-competition-in-the-pharmaceutical-sector-challenges-in-commercializing-pi3ka-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/onkure-therapeutics-faces-stiff-competition-in-the-pharmaceutical-sector-challenges-in-commercializing-pi3ka-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","OKUR"],"gpt_icon":0},{"id":"2518746576","title":"OnKure Therapeutics Is Maintained at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2518746576","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518746576?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:50","pubTimestamp":1741697400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKUR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 08:50 ET (12:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","OPY","LENZ"],"gpt_icon":0},{"id":"2518745263","title":"Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2518745263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518745263?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:40","pubTimestamp":1741696819,"startTime":"0","endTime":"0","summary":"Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OKUR","LENZ","OPY"],"gpt_icon":0},{"id":"2518804137","title":"Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518804137","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518804137?lang=en_us&edition=fundamental","pubTime":"2025-03-11 07:50","pubTimestamp":1741650608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OnKure Therapeutics (OKUR – Research Report) and Eye...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-onkure-therapeutics-okur-and-eyepoint-pharmaceuticals-eypt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-onkure-therapeutics-okur-and-eyepoint-pharmaceuticals-eypt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0109394709.USD","BK4588","BK4007","EYPT","OKUR","BK4137","LU0320765992.SGD","BK4585","HCSG","LU0889565916.HKD"],"gpt_icon":0},{"id":"2518884087","title":"Onkure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2518884087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518884087?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:29","pubTimestamp":1741638552,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT11X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OKUR","BK4139"],"gpt_icon":0},{"id":"2518289788","title":"Onkure Therapeutics: Expansion of Pi3ka Franchise to Include a Pan-Mutant Selective Program; Development Candidate Expected to Be Announced in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518289788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518289788?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:29","pubTimestamp":1741638552,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT11X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OKUR"],"gpt_icon":0},{"id":"2518200992","title":"Press Release: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2518200992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518200992?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:05","pubTimestamp":1741637100,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights. -- PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024. -- Expansion of PI3Ka franchise to include a pan-mutant selective program; development candidate expected to be announced in Q2 2025. -- $111M in cash and cash equivalents expected to be sufficient to fund operations through multiple PIKture-01 clinical readouts and anticipated milestones into Q4 2026. \"The extensive expertise of our research and development team in discovering development candidates with favorable drug properties is our strength, and the entire OnKure team is contributing to the execution of our strategy. This year, we expect to report additional OKI-219 data from PIKture-01, announce our pan-mutant inhibitor program, and declare plans to initiate additional clin","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","LENZ","BK4139"],"gpt_icon":0},{"id":"2516267579","title":"OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2516267579","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516267579?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"BOULDER, Colo., March 04, 2025  -- OnKure Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will present and be available for one-on-one investor meetings at the following investor conferences:. A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET. A live audio webcast will be available through this link and the Investors section of OnKure’s website at www.onkure.com. Following the event, a replay will be available on the OnKure website for at least 90 days.A fireside chat at the Stifel Targeted Oncology Forum, which will be held virtually April 8-9, 2025. Additional information will be available on the OnKure website.For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onkure-therapeutics-present-upcoming-leerink-130000581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OKUR","LENZ","SF","BK4139","BK4127"],"gpt_icon":0},{"id":"2507090185","title":"U.S. RESEARCH ROUNDUP-Apple, Coinbase Global, Nextracker","url":"https://stock-news.laohu8.com/highlight/detail?id=2507090185","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507090185?lang=en_us&edition=fundamental","pubTime":"2025-01-29 14:30","pubTimestamp":1738132221,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apple, Coinbase Global, Nextracker Jan 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Apple, Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nL3N3OP0CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0724618433.USD","LU2089984988.USD","SYK","OKUR","BK4596","LU2517655291.USD","NXT","LU2552382215.SGD","LU1430594728.SGD","LU2506951792.HKD","LU1244550577.SGD","JBLU","LU1366192091.USD","FFIV","FIZN","BK4023","NOW","LU0690374961.EUR","RTX","LU1974910355.USD","MSBI","BK4581","KOPN","LU2506951875.HKD","MANH","BK4516","HLI","NUE","GB00B4LPDJ14.GBP","BK4008","EL","LPTX","LU0823417653.USD","LU2362540622.SGD","LRN","BK4190","LU0708995401.HKD","LU2023250504.SGD","HBCP","PII","NVR","LU2294711713.HKD","LU0320765059.SGD","LU1978683503.SGD","FCNCA","LU2506952097.USD","KMB","LU1280957306.USD","LU2517655374.HKD"],"gpt_icon":1},{"id":"2507508087","title":"Onkure Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2507508087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507508087?lang=en_us&edition=fundamental","pubTime":"2025-01-29 12:43","pubTimestamp":1738125782,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OP03M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OKUR"],"gpt_icon":0},{"id":"2507527765","title":"OnKure Therapeutics Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2507527765","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507527765?lang=en_us&edition=fundamental","pubTime":"2025-01-29 07:10","pubTimestamp":1738105800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKUR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2025 18:10 ET (23:10 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","OKUR"],"gpt_icon":0},{"id":"2490714859","title":"Oppenheimer Remains a Buy on OnKure Therapeutics (OKUR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490714859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490714859?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:46","pubTimestamp":1733921176,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler maintained a Buy rating on OnKure Therapeutics (OKUR – Research Report) today and set a price target of $35.00....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-remains-a-buy-on-onkure-therapeutics-okur?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-remains-a-buy-on-onkure-therapeutics-okur?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","OKUR","BK4127","BK4139"],"gpt_icon":0},{"id":"2490943190","title":"Onkure Therapeutics Inc - No Dose Interruptions, Delays, Reductions, or Discontinuations Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2490943190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490943190?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUABNHDVQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OKUR"],"gpt_icon":0},{"id":"2490809101","title":"Onkure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (Pk) Data From Its First-in-Human Pikture-01 Trial of Oki-219","url":"https://stock-news.laohu8.com/highlight/detail?id=2490809101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490809101?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUABNHDVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OKUR"],"gpt_icon":0},{"id":"2490367094","title":"Onkure Therapeutics Inc - Oki-219 Well Tolerated With No Hyperglycemia and Only Grade 1 Traes","url":"https://stock-news.laohu8.com/highlight/detail?id=2490367094","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490367094?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUABNHDVQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OKUR","BK4139"],"gpt_icon":0},{"id":"2490094491","title":"OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094491","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094491?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832000,"startTime":"0","endTime":"0","summary":"-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported. -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models. -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025. In addition, the Company announced new pre-clinical data that show OKI-219’s synergistic activity, inducing regressions, in combination with SERD + CDK4/6 inhibitors, potentially paving the way for clinical trials in multiple lines of therapy. These clinical and preclinical data are scheduled to be presented during poster sessions at the 2024 San Antonio Breast Cancer Symposium  on December 12, 2024.Patients have been treated with OKI-219 at three dose levels as a single agent: 300 mg BID, 600 mg BID, and 900 mg BID. Across all three levels, a total of 17 patie","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OXoqzmxiGNAcIKHbKuYkgA--~B/aD02OTM7dz05MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f3fa271a082f1465740d75391f7a7645","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OXoqzmxiGNAcIKHbKuYkgA--~B/aD02OTM7dz05MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f3fa271a082f1465740d75391f7a7645"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onkure-announces-encouraging-preliminary-safety-120000915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4585","BK4226","LU1228905037.USD","LU0390134368.USD","BK4139","BR","BK4106","BK4218","BK4548","IE0034235188.USD","LU0545562505.USD","LU1228905540.USD","OKUR","BK4181","BK4588","IE0009354923.USD"],"gpt_icon":0},{"id":"2486061553","title":"OnKure Announces New Date for Upcoming Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2486061553","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486061553?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:31","pubTimestamp":1732573860,"startTime":"0","endTime":"0","summary":"Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CTBOULDER, Colo., Nov.  25, 2024  (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/25/2987121/0/en/OnKure-Announces-New-Date-for-Upcoming-Investor-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKUR"],"gpt_icon":0},{"id":"2482413939","title":"OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2482413939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482413939?lang=en_us&edition=fundamental","pubTime":"2024-11-09 14:01","pubTimestamp":1731132071,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics, Inc. (OKUR) has disclosed a new risk, in the Corporate Activity and Growth category. Onkure Therapeutics, Inc. faces significa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/onkure-therapeutics-faces-post-merger-hurdles-integration-challenges-and-talent-competition-threaten-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/onkure-therapeutics-faces-post-merger-hurdles-integration-challenges-and-talent-competition-threaten-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["POST","BK4212","LENZ","OKUR","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OKUR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-10","symbol":"OKUR","fiscalQuarterEnding":"2024/12","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741579200000,"reportTimeType":"post","actualEps":-1.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OKUR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OKUR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1738123200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OKUR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OKUR","date":"2025-04-23","current":-0.663208,"percent":0.937984,"low":-5.826698,"twenty":-4.478884,"median":-1.720925,"eighty":-1.174736,"high":-0.566743,"avg":-2.420254,"sd":1.594054,"marketCap":34933147},"quantilePoints":[{"date":"2024-10-18","current":-0.566743,"twenty":-0.590487,"median":-0.58695,"eighty":-0.578615,"marketCap":23873500},{"date":"2024-10-25","current":-5.440362,"twenty":-1.566804,"median":-0.588529,"eighty":-0.583857,"marketCap":229169826},{"date":"2024-10-31","current":-5.53853,"twenty":-5.51383,"median":-0.595209,"eighty":-0.585182,"marketCap":233305021},{"date":"2024-11-08","current":-5.443529,"twenty":-5.51383,"median":-5.168028,"eighty":-0.586445,"marketCap":229303220},{"date":"2024-11-15","current":-5.044864,"twenty":-5.465063,"median":-5.164656,"eighty":-0.588845,"marketCap":225434812},{"date":"2024-11-22","current":-4.773218,"twenty":-5.441629,"median":-5.044864,"eighty":-0.591244,"marketCap":213296014},{"date":"2024-11-29","current":-4.603066,"twenty":-5.421362,"median":-4.955311,"eighty":-0.594567,"marketCap":205692591},{"date":"2024-12-06","current":-4.23888,"twenty":-5.387795,"median":-4.77471,"eighty":-2.052213,"marketCap":189418599},{"date":"2024-12-13","current":-3.232892,"twenty":-5.327258,"median":-4.623962,"eighty":-3.414388,"marketCap":144465030},{"date":"2024-12-20","current":-2.403027,"twenty":-5.244271,"median":-4.603066,"eighty":-2.584523,"marketCap":107381670},{"date":"2024-12-27","current":-2.444819,"twenty":-5.224724,"median":-4.480676,"eighty":-2.411385,"marketCap":109249178},{"date":"2025-01-03","current":-2.543328,"twenty":-5.168028,"median":-4.415003,"eighty":-2.435864,"marketCap":113651159},{"date":"2025-01-10","current":-2.331384,"twenty":-5.162633,"median":-4.235895,"eighty":-2.394669,"marketCap":104180229},{"date":"2025-01-17","current":-1.794061,"twenty":-5.159079,"median":-4.098579,"eighty":-2.308697,"marketCap":80169421},{"date":"2025-01-24","current":-1.605998,"twenty":-5.09033,"median":-3.232892,"eighty":-1.908093,"marketCap":71765638},{"date":"2025-01-31","current":-1.740329,"twenty":-5.041282,"median":-2.694077,"eighty":-1.735553,"marketCap":77768340},{"date":"2025-02-07","current":-1.698537,"twenty":-4.988744,"median":-2.570194,"eighty":-1.722418,"marketCap":75900833},{"date":"2025-02-14","current":-1.680626,"twenty":-4.917698,"median":-2.540343,"eighty":-1.700328,"marketCap":75100472},{"date":"2025-02-21","current":-1.629879,"twenty":-4.846055,"median":-2.485118,"eighty":-1.698537,"marketCap":72832785},{"date":"2025-02-28","current":-1.459727,"twenty":-4.775009,"median":-2.435864,"eighty":-1.629879,"marketCap":65229362},{"date":"2025-03-07","current":-1.510474,"twenty":-4.72068,"median":-2.35825,"eighty":-1.588087,"marketCap":67497050},{"date":"2025-03-14","current":-1.170006,"twenty":-4.634708,"median":-2.331384,"eighty":-1.520623,"marketCap":61627741},{"date":"2025-03-21","current":-1.2754,"twenty":-4.622768,"median":-2.038842,"eighty":-1.494951,"marketCap":67179130},{"date":"2025-03-28","current":-1.196325,"twenty":-4.613812,"median":-1.835853,"eighty":-1.463309,"marketCap":63014023},{"date":"2025-04-04","current":-0.992261,"twenty":-4.603066,"median":-1.777643,"eighty":-1.2754,"marketCap":52265363},{"date":"2025-04-11","current":-0.755037,"twenty":-4.555304,"median":-1.746299,"eighty":-1.238668,"marketCap":39770044},{"date":"2025-04-17","current":-0.747384,"twenty":-4.482467,"median":-1.737344,"eighty":-1.209875,"marketCap":39366970},{"date":"2025-04-23","current":-0.663208,"twenty":-4.478884,"median":-1.720925,"eighty":-1.174736,"marketCap":34933147}],"updateTime":1745558386753}}}